Publication Name	World Journal of Psychiatry
Manuscript ID	64830
Country	Australia

Received	2021-02-24 04:57
Peer-Review Started	2021-02-24 05:01
To Make the First Decision
Return for Revision	2021-07-04 02:34
Revised	2021-07-12 01:04
Second Decision	2021-07-29 02:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-07-29 05:53
Articles in Press	2021-07-29 05:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-08-02 08:47
Publish the Manuscript Online	2021-08-12 08:46

ISSN	2220-3206 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Psychiatry
Manuscript Type	Systematic Reviews
Article Title	Therapeutic use of melatonin in schizophrenia: A systematic review
Manuscript Source	Invited Manuscript
All Author List	Cathy Duan, Zoe M Jenkins and David Castle
Funding Agency and Grant Number
Corresponding Author	Zoe M Jenkins, BSc, Research Fellow, Mental Health Service, St. Vincent's Hospital, 46 Nicholson Street, Fitzroy, Melbourne 3065, VIC, Australia. zoe.jenkins@svha.org.au
Key Words	Schizophrenia; Melatonin; Clinical trials; Sleep; Metabolic syndrome; Tardive dyskinesia
Core Tip	This systematic review synthesized the results of clinical trials that have investigated the effect of exogenous melatonin as adjunctive therapy for patients with schizophrenia. Some positive outcomes were demonstrated for sleep improvement and attenuating antipsychotic-induced metabolic side effects. Future investigations are required to determine differential effects of melatonin when used in conjunction with a range of antipsychotic medications.
Publish Date	2021-08-12 08:46
Citation	Duan C, Jenkins ZM, Castle D. Therapeutic use of melatonin in schizophrenia: A systematic review. World J Psychiatr 2021; 11(8): 463-476
URL	https://www.wjgnet.com/2220-3206/full/v11/i8/463.htm
DOI	https://dx.doi.org/10.5498/wjp.v11.i8.463

Full Article (PDF)	WJP-11-463.pdf
Full Article (Word)	WJP-11-463.docx
Manuscript File	64830_Auto_Edited-JPY.docx
Answering Reviewers	64830-Answering reviewers.pdf
Audio Core Tip	64830-Audio core tip.mp3
Biostatistics Review Certificate	64830-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	64830-Conflict-of-interest statement.pdf
Copyright License Agreement	64830-Copyright license agreement.pdf
Peer-review Report	64830-Peer-review(s).pdf
Scientific Misconduct Check	64830-Scientific misconduct check.pdf
Scientific Editor Work List	64830-Scientific editor work list.pdf